View Filing Data

Print Document View Excel Document

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2014	Mar. 27, 2015	Jun. 30, 2014
Document Information [Line Items]
Entity Registrant Name	ATOSSA GENETICS INC
Entity Central Index Key	0001488039
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ATOS
Entity Common Stock, Shares Outstanding		25,396,124
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2014
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 32,864,598

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$ 8,500,718	$ 6,342,161
Accounts receivable, net	297,958	139,072
Prepaid expenses	247,207	280,627
Inventory, net	39,788	0
Total current assets	9,085,671	6,761,860
Furniture and equipment, net	357,532	163,147
Intangible assets, net	1,920,645	4,395,633
Deferred financing costs	351,961	651,961
Other assets	48,193	36,446
Total assets	11,764,002	12,009,047
Current liabilities
Accounts payable	594,357	248,142
Accrued expenses	444,861	295,310
Deferred rent	0	48,157
Payroll liabilities	1,056,705	580,645
Product recall liabilities	0	211,493
Short-term lease obligations	76,025	9,681
Other current liabilities	42,228	8,148
Total current liabilities	2,214,176	1,401,576
Deferred rent, net of current portion	2,483	0
Long-term lease obligations	49,216	5,820
Total liabilities	2,265,875	1,407,396
Commitments and contingencies (note 12)
Stockholders' equity
Preferred stock - $.001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding	0	0
Common stock - $.001 par value; 75,000,000 shares authorized, 24,564,058 and 18,574,334 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively	24,564	18,574
Additional paid-in capital	44,648,103	31,099,691
Accumulated deficit	(35,174,540)	(20,516,614)
Total stockholders' equity	9,498,127	10,601,651
Total liabilities and stockholders' equity	$ 11,764,002	$ 12,009,047

CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	75,000,000	75,000,000
Common stock, shares issued	24,564,058	18,574,334
Common stock, shares outstanding	24,564,058	18,574,334

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Revenue
Diagnostic testing service	$ 525,954	$ 409,118
Product sales	0	223,440
Total revenue	525,954	632,558
Cost of revenue
Diagnostic testing service	340,658	105,764
Product sales	0	239,755
Total cost of revenue	340,658	345,519
Loss on obsolete inventory	0	149,946
Gross profit	185,296	137,093
Selling expenses	1,271,705	1,257,791
Research and development expenses	2,577,465	1,105,110
General and administrative expenses	8,625,917	8,558,835
Impairment of intangible assets	2,352,626	0
Total operating expenses	14,827,713	10,921,736
Operating loss	(14,642,417)	(10,784,643)
Interest income	260	295
Interest expense	(15,769)	(360)
Net loss before income taxes	(14,657,926)	(10,784,708)
Income taxes	0	0
Net loss	$ (14,657,926)	$ (10,784,708)
Loss per common share - basic and diluted (in dollars per share)	$ (0.61)	$ (0.70)
Weighted average shares outstanding, basic & diluted (in shares)	24,038,578	15,484,414

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2012	$ 5,175,535	$ 12,919	$ 14,894,522	$ (9,731,906)
Balance (in shares) at Dec. 31, 2012		12,919,367
Issuance of common shares for cash	12,303,745	$ 2,733	12,301,012	0
Issuance of common shares for cash (in shares)		2,733,333
Issuance of common shares for services	180,252	$ 67	180,185	0
Issuance of common shares for services (in shares)		66,696
Issuance of common shares for capital raising fees, net	651,961	$ 625	651,336	0
Issuance of common shares for capital raising fees , net (in shares)		625,000
Issuance of common shares for exercise of warrants	1,621,182	$ 2,224	1,618,958	0
Issuance of common shares for exercise of warrants (in shares)		2,224,392
Stock option exercises	9,924	$ 6	9,918	0
Stock option exercises (in shares)		5,546
Compensation cost for stock options granted to executives and employees	1,443,760	$ 0	1,443,760	0
Net loss	(10,784,708)	0	0	(10,784,708)
Balance at Dec. 31, 2013	10,601,651	$ 18,574	31,099,691	(20,516,614)
Balance (in shares) at Dec. 31, 2013		18,574,334
Issuance of common shares for cash	14,002,162	$ 5,834	13,996,328	0
Issuance of common shares for cash (in shares)		5,834,234
Issuance of common shares for services	0	$ 23	(23)	0
Issuance of common shares for services (in shares)		22,728
Issuance of common shares for capital raising fees, net	(1,378,417)	$ 0	(1,378,417)	0
Issuance of common shares for capital raising fees , net (in shares)		0
Issuance of common shares for exercise of warrants	32,000	$ 20	31,980	0
Issuance of common shares for exercise of warrants (in shares)		20,000
Stock option exercises	200,000	$ 113	199,887
Stock option exercises (in shares)		112,762
Compensation cost for stock options granted to executives and employees	698,657	$ 0	698,657	0
Net loss	(14,657,926)	0	0	(14,657,926)
Balance at Dec. 31, 2014	$ 9,498,127	$ 24,564	$ 44,648,103	$ (35,174,540)
Balance (in shares) at Dec. 31, 2014		24,564,058

CONSOLIDATED STATEMENT OF CASHFLOW - USD ($)	12 Months Ended
CONSOLIDATED STATEMENT OF CASHFLOW - USD ($)	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (14,657,926)	$ (10,784,708)
Adjustments to reconcile net loss to net cash used in operating activities:
Common shares issued for services	0	178,280
Compensation cost for stock options granted	698,657	1,443,760
Loss on reduction on obsolete inventory	0	149,946
Impairment of long-lived assets	2,352,626	158,292
Depreciation and amortization	564,456	472,934
Bad debt expenses	209,288	354,861
Changes in operating assets and liabilities:
Accounts receivable	(368,174)	(352,267)
Inventory	(39,788)	(149,946)
Prepaid expenses	(51,581)	(57,994)
Security deposits	(11,747)	0
Accounts payable	346,215	(58,583)
Payroll liabilities	476,060	268,480
Deferred rent	(45,674)	48,157
Product recall liabilities	(211,493)	211,493
Accrued expenses	149,551	(704,372)
Other current liabilities	34,080	(8,377)
Net cash used in operating activities	(10,555,450)	(8,830,044)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of furniture and equipment	(146,058)	(244,442)
Purchases of intangible assets	(197,199)	(245,373)
Net cash used in investing activities	(343,257)	(489,815)
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from issuance of common stock and warrants	13,155,745	13,936,823
Payments on capital lease obligations	(98,481)	0
Net cash provided by financing activities	13,057,264	13,936,823
NET INCREASE IN CASH AND CASH EQUIVALENTS	2,158,557	4,616,964
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	6,342,161	1,725,197
CASH AND CASH EQUIVALENTS, ENDING OF YEAR	8,500,718	6,342,161
SUPPLEMENTAL DISCLOSURES:
Interest paid	15,769	360
NONCASH INVESTING AND FINANCING ACTIVITIES:
Reclassification of furniture and equipment to prepaid expenses	15,000	0
Furniture and fixtures acquired through capital lease	206,702	0
Common stock issued as commitment fee under stock purchase agreement	$ 0	$ 2,387,250

NATURE OF OPERATIONS

12 Months Ended

Dec. 31, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations [Text Block]

NOTE 1: NATURE OF OPERATIONS

Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company’s operations began in December 2008 with the negotiations for the acquisition of the Mammary Aspirate Specimen Cytology Test System, or the MASCT System, patent rights and assignments and the FDA clearance for marketing, which acquisition was completed in January 2009. The Company was formed to develop and market the MASCT System, which is a medical device that collects specimens of nipple aspirate fluid (NAF). The Company’s fiscal year ends on December 31.

In December 2011, the Company established the National Reference Laboratory for Breast Health, Inc., or NRLBH, as a wholly-owned subsidiary. NRLBH is the Company’s CLIA-certified laboratory which performs the Company’s NAF cytology test on NAF specimens including those collected with the MASCT System. The current version of the MASCT System is called the ForeCYTE Breast Aspirator. The NRLBH is providing other test services, including the pharmacogenomics test, and is developing other tests such as the ArgusCYTE test on blood samples from breast cancer survivors to detect circulating tumor cells.

In September 2012, the Company acquired the assets of Acueity Healthcare, Inc. (“Acueity”). The purchased assets included the intellectual property rights related to the Viaduct Miniscope and accessories, the Manoa Breast Biopsy system, the Excisor Bioptome, the Acueity Medical Light Source, the Viaduct Microendoscope and accessories, and cash in the amount of $400,000. The microendoscopes are less than 0.9 mm outside diameter and can be inserted into a milk duct. This permits a physician to pass a microendoscope into the milk duct system of the breast and view the duct system via fiberoptic video images. Abnormalities that are visualized can then be biopsied from inside the duct with the biopsy tools that are inserted adjacent to the microendoscope. The patents relate to intraductal diagnostic and therapeutic devices and methods of use. The Company did not, however, acquire an inventory of these diagnostic tools, manufacturing capabilities or any personnel to market and sell the tools. The Company cannot provide any assurance that it will be successful commercializing these tools.

GOING CONCERN

12 Months Ended

Dec. 31, 2014

Going Concern Disclosure [Abstract]

Going Concern Disclosure [Text Block]

NOTE 2: GOING CONCERN

The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative operating cash flows since inception. For the year ended December 31, 2014, the Company recorded a net loss of approximately $14.7 million and used approximately $10.5 million of cash in operating activities. As of December 31, 2014, the Company had approximately $8.5 million in cash and cash equivalents and working capital of approximately $6.9 million. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that any additional capital that it is able to obtain, if any, will be sufficient to meet its needs, or that any such financing will be obtainable on acceptable terms. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail is commercial activities. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern.

Management’s Plan to Continue as a Going Concern:

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management’s plans to obtain such resources for the Company include (1) obtaining capital from the sale of its equity securities during 2015, (2) sales of the ForeCYTE and FullCYTE Breast Aspirators and laboratory service revenue beginning in early 2015, and (3) short-term borrowings from banks, stockholders or other related party(ies), if needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually to secure other sources of financing and attain profitable operations.

SUMMARY OF ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

NOTE 3: SUMMARY OF ACCOUNTING POLICIES

Basis of Presentation:

The accompanying consolidated financial statements have been prepared pursuant to the rules of the Securities and Exchange Commission ("SEC") and in accordance with U.S. generally accepted accounting principles ("GAAP"). The accompanying consolidated financial statements include the financial statements of Atossa Genetics Inc. and its wholly-owned subsidiary, NRLBH. All significant intercompany account balances and transactions have been eliminated in consolidation.

Use of Estimates:

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Recently Issued Accounting Pronouncements:

In May 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers: Topic 606 (“ASU 2014-09”), to supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company in the first quarter of 2017 using either of two methods: (i) retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09; or (ii) retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09. The Company is currently evaluating the impact of its pending adoption of ASU 2014-09 on its consolidated financial statements.

In June 2014, FASB issued ASU 2014-10, Elimination of Development Stage Entity Requirements. This ASU eliminates the concept of Development Stage Entities (DSE’s) from U.S. GAAP and is intended to result in cost-savings for certain entities, such as start-ups or research and development entities. As a result of these changes, the financial statements of developing entities no longer need to meet the inception-to-date income cash flow and equity information; developing companies do not have to label their financial statements as “development stage”; and certain disclosures related to the nature of the entity’s development stage activities are no longer required. The Company adopted the provisions of this ASU during the year ended December 31, 2014.

In August, 2014, FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This ASU requires the management to determine whether substantial doubt exists regarding the entity’s going concern presumption, which generally refers to an entity’s ability to meet its obligations as they become due. If substantial doubt exists but is not alleviated by management’s plan, the footnotes must specifically state that “there is substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued.” In addition, if substantial doubt exists, regardless of whether such doubt was alleviated, entities must disclose (a) principal conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern (before consideration of management’s plans, if any); (b) management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations; and (c) management’s plans that are intended to mitigate the conditions or events that raise substantial doubt, or that did alleviate substantial doubt, about the entity’s ability to continue as a going concern. If substantial doubt has not been alleviated, these disclosures should become more extensive in subsequent reporting periods as additional information becomes available. In the period that substantial doubt no longer exists (before or after considering management’s plans), management should disclose how the principal conditions and events that originally gave rise to substantial doubt have been resolved. The ASU applies prospectively to all entities for annual periods ending after December 15, 2016, and to annual and interim periods thereafter. Early adoption is permitted. The Company has not yet adopted the provisions of ASU 2014-15.

Reclassifications:

The prior period deferred financing costs have been reclassified to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.

Certain prior period accrued expenses and current liabilities have been reclassified as accounts payable, payroll liabilities, and lease obligations to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.

Revenue Recognition

Overview

The Company recognizes product and service revenue in accordance with GAAP when the following overall fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or the service has been performed, (iii) the Company’s price to the customer is fixed or determinable, and (iv) collection of the resulting accounts receivable is reasonably assured.

Product Revenue

During 2013, the Company recognized revenue for sales of the MASCT kits and devices on an accrual basis for sales to distributors when the above four criteria were met. For sales of MASCT kits and devices sold directly to physicians, the revenue was typically recognized upon receipt of cash as the Company had an insufficient history on which to determine collectability. Shipping documents and the completion of any customer acceptance requirements, when applicable, were used to verify product delivery.

Service Revenue

The Company records revenue for diagnostic testing on an accrual basis at the Medicare allowed and invoiced amount. Amounts invoiced above the Medicare amount, namely non-Medicare, are not recognized on an accrual basis and instead are recognized on a cash basis as received. Diagnostic testing revenue at the Medicare rate is recognized upon completion of the test, communication of results to the patient’s physician, and when collectability is reasonably assured. Customer purchase orders and/or contracts are generally used to determine the existence of an arrangement. Once the Company has historical sales and can determine the proper amount to recognize as uncollectible, it will then begin to recognize the entire amount, both Medicare and non-Medicare billing, on an accrual basis, with an offsetting allowance for doubtful accounts recorded based on history. The Company estimates a proper allowance for doubtful accounts based on the diagnostic testing revenue collection history.

Cost of Revenue

Cost of revenue consists of the costs of diagnostic testing services and costs of product sales. Costs of diagnostic testing services primarily include direct costs of material, direct labor, equipment, and shipping to process the patient samples (including pathology, quality control analysis, and shipping charges to transport tissue sample) in the Company’s laboratory. Costs associated with performing the Company's tests are recorded as tests are processed. Costs recorded for tissue sample processing and shipping charges represent the cost of all the tests processed during the period regardless of whether revenue was recognized with respect to that test. Cost of product sales for 2013 primarily included the manufacturing cost of the MASCT System for sales to distributors, which was recorded upon transfer of ownership of the goods.

Cash and Cash Equivalents

Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less.

Inventory

The Company’s inventories consist of laboratory supply inventory and product inventory. Inventories are stated at lower of cost or market. Cost is determined on a moving-average basis. Costs of inventories include purchases and related costs incurred in delivering the products to their present location and condition. Market value is determined by reference to selling prices after the balance sheet date or to management’s estimates based on prevailing market conditions. Inherent in the lower of cost or market calculation are several significant judgments based on a review of the aging of the inventory, inventory movement of products, economic conditions, and replacement costs. Management periodically evaluates the composition of its inventories at least quarterly to identify slow-moving and obsolete inventories to determine if any valuation allowance is required. During the course of the Company’s recall which commenced in October 2013, the Company recalled all of the MASCT Systems. Based on management’s assessment of those devices and the pending FDA clearance, the Company recorded $149,946 of losses on obsolete inventory for the year ended December 31, 2013 as a result of reducing the carrying value of the MASCT systems inventory to zero. As of December 31, 2014 and 2013, inventories amounted to $39,788 and $0, respectively.

Accounts Receivable

Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for doubtful accounts, as needed. The Company assesses the collectability of accounts receivable based primarily upon the creditworthiness of the customer as determined by credit checks and analysis, as well as the customer’s payment history. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company’s allowance for doubtful accounts as of December 31, 2014 and 2013 was $564,149 and $354,861, respectively. Bad debt expense is included in general and administrative expense on the Company’s consolidated statements of operations. Bad debt expense and was $209,288 and $354,861 for the years ended December 31, 2014 and 2013, respectively.

Furniture and Equipment

Furniture and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When furniture and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations.

Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:

		Useful Life (in years)
Machinery and equipment		3 - 5
Leasehold improvements		2.083

The Company applies the provisions of FASB ASC Topic 360 (ASC 360), “Property, Plant, and Equipment” which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with ASC 360, at least on an annual basis. ASC 360 requires the impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal. For the years ended December 31, 2014 and 2013, $0 and $158,292 was recorded as impairment of property and equipment, respectively.

Intangible Assets

Intangible assets consist of intellectual property and software acquired. Intangibles are reviewed at least annually for impairment or whenever events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Estimating future cash flows related to an intangible asset involves significant estimates and assumptions. If our assumptions are not correct, there could be an impairment loss or, in the case of a change in the estimated useful life of the asset, a change in amortization expense.

The Company has evaluated and reprioritized its research and development pipeline based on recent business strategies, and as a result has delayed plans to develop and invest further in Acueity patents and technologies for at least the next year. Because of these changed business plans related to the Acueity assets, the Company has re-evaluated the assets for potential impairment. The Company has concluded that these assets are partially impaired and has recorded asset impairment charges of $2,352,626 for the year ended December 31, 2014 to adjust the carrying value of these intangible assets to their estimated fair values as of December 31, 2014.

The Company determined the fair values of the Acueity intangibles using an income approach. When available and appropriate, the Company uses comparative market multiples to corroborate discounted cash flow results. For purposes of the income approach, fair value is determined based on the present value of estimated future cash flows to be generated from development of products using the patented technology acquired in the Acueity transaction based on our current plans, discounted at an appropriate risk-adjusted rate. The Company uses its internal forecasts to estimate future cash flows and include an estimate of long-term future growth rates based on its most recent views of the outlook of the business. The Company uses discount rates that are commensurate with the risk and uncertainty inherent in the business and in its internally developed forecasts. Discount rates used in the Company’s valuations for these intangible assets ranged from 18% to 21%.

Amortization is computed using the straight-line method over the estimate useful lives of the assets as follows:

		Useful Life (in years)
Patents		7 - 12
Software		3

Share-Based Payments

The Company follows the provisions of ASC Topic 718, Compensation - Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period.

The fair value of each option grant is estimated using the Black-Scholes option-pricing model, which requires assumptions regarding the expected volatility of the stock options, the expected life of the options, an expectation regarding future dividends on the Company’s common stock, and estimation of an appropriate risk-free interest rate. The Company’s expected common stock price volatility assumption is based upon the volatility of a basket of companies that it considers comparable to the Company given that the Company’s own stock has not been traded for a sufficient period to establish a volatility assumption based on its own historical data as our stock began trading in November 2012. As there becomes additional data regarding the Company’s own stock price volatility, it plans to incorporate that data in its volatility assumption. The expected life assumption for stock options grants was based upon the simplified method provided for under ASC 718-10, which averages the contractual term of the options of ten years with the average vesting term of four years. The dividend yield assumption of zero is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends in the future. The risk-free interest rate used for each grant was based upon prevailing short-term interest rates over the expected life of the options.

The Company has estimated an annualized forfeiture rate of 10.0% for options granted. The Company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated.

PREPAID EXPENSES

12 Months Ended

Dec. 31, 2014

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses [Text Block]

NOTE 4: PREPAID EXPENSES

Prepaid expenses consisted of the following:

	December 31,		December 31,
	2014		2013
Prepaid insurance	$	87,633	$	112,517
Tradeshow and other marketing events		50,000		-
Prepaid hardware and software		38,268		131,204
Retainer and security deposits		25,000		36,906
Lab supplies		14,976		-
Other		31,330		-
Total prepaid expenses	$	247,207	$	280,627

FURNITURE AND EQUIPMENT

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

NOTE 5: FURNITURE AND EQUIPMENT

Furniture and equipment consisted of the following:

	December 31,		December 31,
	2014		2013
Machinery and equipment	$	522,813	$	168,532
Leasehold improvements		93,665		93,665
Capitalized new product development cost		-		15,000
Furniture and equipment		616,478		277,197
Less: accumulated depreciation		(258,946)		(114,050)
Total furniture and equipment, net	$	357,532	$	163,147

As of December 31, 2014, assets under capital lease of $206,702 are included in machinery and equipment. Depreciation expense for the years ended December 31, 2014 and 2013 was $144,896 and $82,970, respectively.

INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

NOTE 6: INTANGIBLE ASSETS

Intangible assets consisted of the following:

	December 31,		December 31,
	2014		2013
Patents	$	1,630,000	$	4,794,853
Capitalized license costs		200,000		-
Software		203,038		105,839
Intangible assets		2,033,038		4,900,692
Less: accumulated amortization		(112,393)		(505,059)
Total intangible assets, net	$	1,920,645	$	4,395,633

Intangible assets amounted to $1,920,645 and $4,395,633 as of December 31, 2014 and December 31, 2013, respectively, and consisted of patents, capitalized license costs and software acquired. The acquired software mainly consisted of $58,000 in laboratory software, $31,500 in the newly developed Company website and $72,200 in internal use SAP Business One ERP system which is under development. The amortization period for the purchased software is three years. Amortization expense related to software for the years ended December 31, 2014 and 2013 was $28,903 and $24,308, respectively.

Patents amounted to $1,630,000 and $4,794,853 as of December 31, 2014 and 2013, respectively, and mainly consisted of patents acquired from Acueity on September 30, 2012 in an asset purchase transaction. Patent assets are amortized based on their determined useful life, and tested annually for impairment. As discussed in Note 2, the Company has evaluated and reprioritized its research and development pipeline based on recent business strategies, and as a result has delayed plans to develop and invest further in Acueity patents for at least the next year. Because of these changed business plans related to the Acueity assets, the Company has re-evaluated the assets for potential impairment. The Company has concluded that these assets are partially impaired and the Company has recorded asset impairment charges of $2,352,626 during the year ended December 31, 2014.

The amortization period of intangible assets is from 7 to 12 years. Amortization expense related to intangible assets was $373,990 and $365,656 for years ended December 31, 2014 and 2013, respectively.

Capitalized license costs consist of fees paid to A5 Genetics KFT, Corporation, pursuant to which the Company received the world-wide (other than the European Union) exclusive license to use the software in the NextCYTE test. Amortization expense related to license costs was $16,667 for the year ended December 31, 2014.

Future estimated amortization expenses as of December 31, 2014 for the five succeeding years and thereafter is as follows:

As of December 31,		Amounts
2015	$	213,776
2016		224,804
2017		193,443
2018		169,015
2019		169,015
Thereafter		950,592
	$	1,920,645

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

PAYROLL LIABILITIES

12 Months Ended

Dec. 31, 2014

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

NOTE 7: PAYROLL LIABILITIES:

Payroll liabilities consisted of the following:

	December 31,		December 31,
	2014		2013
Accrued bonus payable	$	752,828	$	408,362
Accrued payroll liabilities		109,653		152,400
Accrued payroll tax liabilities		194,224		19,883
Total payroll liabilities	$	1,056,705	$	580,645

STOCKHOLDERS' EQUITY

12 Months Ended

Dec. 31, 2014

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

NOTE 8: STOCKHOLDERS’ EQUITY

The Company is authorized to issue a total of 85,000,000 shares of stock consisting of 75,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. The Company has designated 750,000 shares of Series A Junior Participating Preferred Stock, par value $0.001 per share through the filing of a certificate of designation with the Delaware Secretary of State.

On May 19, 2014, the Company adopted a stockholder rights agreement which provides that all stockholders of record on May 26, 2014 received a non-taxable distribution of one preferred stock purchase right for each share of the Company’s common stock held by such stockholder. Each right is attached to and trades with the associated share of common stock. The rights will become exercisable only if one of the following occurs: (1) a person becomes an “Acquiring Person” by acquiring beneficial ownership of 15% or more of the Company’s common stock (or, in the case of a person who beneficially owned 15% or more of the Company’s common stock on the date the stockholder rights agreement was executed, by acquiring beneficial ownership of additional shares representing 2.0% of the Company’s common stock then outstanding (excluding compensatory arrangements)), or (2) a person commences a tender offer that, if consummated, would result in such person becoming an Acquiring Person. If a person becomes an Acquiring Person, each right will entitle the holder, other than the Acquiring Person and certain related parties, to purchase a number of shares of the Company’s common stock with a market value that equals twice the exercise price of the right. The initial exercise price of each right is $15.00, so each holder (other than the Acquiring Person and certain related parties) exercising a right would be entitled to receive $30.00 worth of the Company’s common stock. If the Company is acquired in a merger or similar business combination transaction at any time after a person has become an Acquiring Person, each holder of a right (other than the Acquiring Person and certain related parties) will be entitled to purchase a similar amount of stock of the acquiring entity.

2014 Public Offering of Common Stock and Warrants

On January 29, 2014, the Company closed a public offering of 5,834,234 units at the price of $2.40 per unit for total gross proceeds of approximately $14.0 million (the “2014 Public Offering”). Each unit consists of one share of common stock and a warrant to purchase 0.20 of a share of common stock (the “2014 Investor Warrants”). The 2014 Investor Warrants are exercisable at $3.00 per share and callable by the Company if our stock trades above $6.00 per share if certain conditions are met.

Placement Agent Fees

In connection with the 2014 Public Offering, the Company paid Dawson James Securities, Inc. (the “Placement Agent”), a cash fee equal to 7% of the gross proceeds from sale of the units, which resulted in a payment to the Placement Agent of an aggregate of $980,151 (the “Placement Agent Fee”). In addition, the Company entered into Warrant Agreements with the Placement Agent pursuant to which the Placement Agent received a warrant to purchase 175,027 shares of common stock, or 3% of the aggregate number of shares sold in the offering (the “2014 Placement Agent Warrants” and together with the 2014 Investor Warrants, the “2014 Warrants”). The 2014 Placement Agent Warrant entitles the Placement Agent to purchase 175,027 shares of the Company’s common stock at $3.00 per share. The cash payment of $980,151 for 2014 Placement Agent Fee and the $121,707 aggregated initial fair value of the 2014 Placement Agent Warrants (see Fair Value Considerations below) were directly attributable to an actual offering and were charged through additional paid-in capital in accordance with the SEC Staff Accounting Bulletin (SAB) Topic 5A.

Warrants

The 2014 Warrants are exercisable at any time commencing after January 29, 2014 (the “Initial Exercise Date”). Subject to the call right described above, the 2014 Warrants shall expire and no longer be exercisable on the fifth anniversary of the Initial Exercise Date (the “Expiration Date”). The 2014 Warrants cannot be exercised on a cashless basis. There are no redemption features embodied in the 2014 Warrants and they have met the conditions for equity classification.

Fair Value Consideration

The Company’s accounting for the issuance of the 2014 Warrants required the estimation of fair values of the financial instruments. The development of fair values of financial instruments requires the selection of appropriate methodologies and the estimation of often subjective assumptions. The Company selected the valuation techniques based upon consideration of the types of assumptions that market participants would likely consider in exchanging the financial instruments in market transactions. The 2014 Warrants were valued using a Black-Scholes-Merton Valuation Technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to assess the fair value of these instruments.

The 2014 Investor Warrants and the 2014 Placement Agent Warrants were valued at $834,986 or $0.72 per warrant, and $121,707 or $0.70 per warrant, respectively. The following tables reflect assumptions used to determine the fair value of the 2014 Warrants:

	Fair	January 29, 2014
	Value Hierarchy Level	2014 Investor Warrants			Placement Agent Warrants

Indexed shares			1,166,849			175,027
Exercise price		$	3.00		$	3.00

Significant assumptions:
Stock price	1	$	2.50		$	2.47
Remaining term	3		5 years			5 years
Risk free rate	2		1.45	%		1.42	%
Expected volatility	3		37.96	%		37.95	%

Outstanding Warrants

As of December 31, 2014, warrants to purchase 6,033,426 shares of common stock were outstanding including:

	Outstanding Warrants to purchase shares	Exercise price		Expiration date

2011 private placement	4,252,050	$	1.25 - 1.60	June 23, 2016
Acueity warrants	325,000		5.00	September 30, 2017
2014 public offering	1,166,849		3.00	January 29, 2019
Placement agent fees for Company’s offerings	242,027		2.12 – 12.43	March - November, 2018
Outside consulting	47,500	$	4.24	January 14, 2018

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

NET LOSS PER SHARE

12 Months Ended

Dec. 31, 2014

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

NOTE 9: NET LOSS PER SHARE

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented, diluted net loss per common share is the same as basic net loss per common share.

The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share for the years ended December 31, 2014 and 2013:

	Year Ended December 31,
	2014	2013
Options to purchase common stock	3,675,634	2,282,719
Warrants to purchase common stock	6,033,426	4,751,550
Restricted stock units	-	-
Total	9,709,060	7,034,269

INCOME TAXES

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

NOTE 10: INCOME TAXES

The Company accounts for income taxes using the asset and liability method, under which deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

The Company did not record an income tax benefit for its losses incurred in 2014 or 2013 due to uncertainty regarding utilization of its net operating loss carryforwards and due to its history of losses. The benefit for income taxes differs from the benefit computed by applying the federal statutory rate to loss before income taxes as follows:

	Year Ended December 31,
	2014		2013
Expected federal income tax benefit	$	(4,983,700)	$	(3,774,648)
Share-based compensation		36,100		-
Other permanent items		9,000		4,363
Effect of change in valuation allowance		4,938,600		3,770,285
Actual federal income tax benefit	$	-	$	-

The components of net deferred tax assets are as follows:

	As of December 31,
	2014		2013
Deferred tax assets, current:
Allowance for doubtful accounts	$	191,900	$	120,700
Deferred rent		900		16,400
Accrued vacation		30,400		16,400
Accrued bonuses		228,100		-
Obsolete inventory		48,400		51,000
Valuation allowance, current		(499,700)		(204,500)
Net deferred tax asset, current		-		-

Deferred tax assets, long term:
Fixed assets, net		-		8,900
Intangible assets, net		841,800		29,000
Allowance for loss on fixed assets		53,800		53,800
Contribution, carryforward		300		-
Share-based compensation		732,400		546,600
Net operating loss carryforwards		9,772,300		6,144,800
Valuation allowance, long term		(11,397,400)		(6,783,100)
Deferred tax asset, long term		3,200		-

Deferred tax liabilities
Fixed assets, net		(3,200)		-
Net deferred tax asset, long term		-		-
Net deferred tax asset	$	-	$	-

The Company has incurred net operating losses from inception. At December 31, 2014, the Company had domestic federal net operating loss carryforwards of approximately $28,700,000 which are available to reduce future taxable income. These federal net operating loss carryforwards, expire at various dates beginning in 2029 through 2034. The Company recorded a valuation allowance against all of its net deferred tax assets of $11,897,100 and $6,987,600 as of December 31, 2014 and 2013, respectively.

Based on an assessment of all available evidence including, but not limited to the Company’s limited operating history in its core business and lack of profitability, uncertainties of the commercial viability of its technology, the impact of government regulation and healthcare reform initiatives, and other risks normally associated with biotechnology companies, the Company has concluded that it is more likely than not that these net operating loss carryforwards and credits will not be realized and, as a result, a full valuation allowance has been recorded against the Company’s deferred income tax assets.

The Company files income tax returns in the U.S. The Company is subject to tax examinations for the 2011 tax year and beyond. The Company has no unrecognized tax positions and does not believe there will be any material changes in its unrecognized tax positions over the next 12 months. The Company has not incurred any interest or penalties related to unrecognized tax positions. In the event that the Company is assessed interest or penalties at some point in the future, they will be classified in the financial statements as general and administrative expense.

CONCENTRATION OF CREDIT RISK

12 Months Ended

Dec. 31, 2014

Risks and Uncertainties [Abstract]

Concentration Risk Disclosure [Text Block]

NOTE 11: CONCENTRATION OF CREDIT RISK

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000. As of December 31, 2014 and 2013, the Company had $ 8,250,718 and $ 6,092,161 in excess of the FDIC insured limit, respectively.

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

NOTE 12: COMMITMENTS AND CONTINGENCIES

Lease Commitments

The future minimum lease payments due subsequent to December 31, 2014 under all non-cancelable operating and capital leases for the next five years are as follows:

	Operating Leases		Capital Leases
Year Ending December 31,	Amount		Amount
2015	$	499,267	$	76,025
2016		478,210		49,216
2017		119,333		-
2018		13,439		-
2019		13,439		-
Total minimum lease payments	$	1,123,688	$	125,241

The total rent expense for 2014 and 2013, respectively, is as follows:

Year Ending December 31,	2014		2013
Research and development expenses	$	227,996	$	214,301
General and administrative expenses		149,174		121,201
Total rent expense	$	377,170	$	335,502

Affymetrix Purchase Commitment

In connection with the development of the NextCYTE test by the NRLBH, the NRLBH entered into an “OwnerChip Program Agreement” with Affymetrix, Inc. (“Affymetrix”), a manufacturer of GeneChip Systems, where Affymetrix has agreed to loan a GeneChip System 3000Dx v.2 (“instrument”) to the Company if it purchases and takes delivery of a minimum thirty GeneChip Human Genome U133 Plus 2.0 (30-pack) arrays at $21,590 per 30 pack for the next three years for a total purchase obligation of $647,700 with a minimum purchase of ten 30-pack arrays per contract year. At the end of the three year contract, upon fulfillment of the purchase commitment, the instrument title and ownership transfer to the NRLBH at no additional cost. Because the Company takes ownership of the equipment at the completion of the three-year contract, the Company determined that the arrangement represents a capital lease for the equipment. The Company recorded $206,702 as a capital lease for the equipment and began amortizing the equipment on a straight line basis over five years. In addition to the GeneChip Human Genome, the NRLBH must purchase a two year service contract for $51,600 to cover maintenance of the instrument during the contract period. The NRLBH placed an initial order for four 30-pack arrays during 2013 for $94,723. In September 2014, the NRLBH purchased six additional 30-pack arrays for $142,005.

The future minimum payments for the Affymetrix capital lease are as follows:

Year Ending December 31,	Amount
2015	$	70,204
2016		49,216
Total minimum lease payments	$	119,420

A5 Software Development Commitment

On June 10, 2013 the Company entered into an irrevocable license and service agreement with A5 Genetics KFT, Corporation (“A5 Genetics”), pursuant to which the Company received the world-wide (other than the European Union) exclusive license to the software used in the NextCYTE test. The Company has the right to prosecute patents related to this software, two of which the Company has filed in the United States. The patent applications have been assigned to the Company. The Company paid a one-time fee of $ 100,000 to A5 Genetics in 2013 and in March 2014 the Company completed software validation and paid an additional $ 100,000 to A5 Genetics. The Company is obligated to pay up to an additional $ 1.2 million to A5 Genetics upon receiving the regulatory clearance for NextCYTE test. The Company must also pay a royalty of $ 50 for each NextCYTE test performed and a service fee of $65 for each NextCYTE test performed. The NextCYTE test is still in validation stage and no royalty or service fees have been paid as of December 31, 2014. The agreement terminates on the later of June 10, 2023 or the expiration of the latest patents covering the software.

Luminex Reagent Rental Agreement and Assay License Agreement

On September 2, 2014, in connection with the development of a pharmacogenomics test by the NRLBH, the NRLBH entered into a three year rental agreement with Luminex Corporation (Luminex), which provides that the NRLBH acquires the right to use Luminex instruments, including accessories, peripherals and options (the “System”) at no cost if the NRLBH purchases goods (the “Products”) at agreed upon quantities and prices for the next three years. The minimum purchases of Products under the agreement are $452,408 per year. The title to the System remains with Luminex and the NRLBH is required to return the System to Luminex at the end of the three year rental agreement.

BioVentive Laboratory Marketing Service Agreement

On August 28, 2014, NRLBH entered into a three year Laboratory Marketing Services Agreement with BioVentive, Inc. (“BioVentive”), which provides that BioVentive market and promote the NRLBH laboratory tests to licensed physicians practicing medicine for a fee. The agreement may be terminated prior to the end of the three year term by either party for material breach that is not cured and the NRLBH may terminate if BioVentive fails to meet certain minimums or if the NRLBH undergoes a change of control. If the agreement is terminated by the NRLBH for any reason other than for cause (which includes a material uncured breach by BioVentive or if BioVentive fails to meet certain minimums), the NRLBH is required to pay BioVentive a termination fee equal to approximately three months of fees otherwise payable to BioVentive.

Targeted Medical Education (TME) Master Service Agreement

On September 1, 2014, the NRLBH entered into a three year agreement with TME Research LLC (TME) which requires TME to provide to the NRLBH 100 tissue specimens in connection with the development of the NextCYTE test. Fees payable to TME under the agreement includes $99,600 up front, $31,500 upon supplying the first 25 specimens and $31,500 at the time of final delivery of all specimens. The agreement is terminable with 60 days prior written notice or immediately upon a material breach. As of December 31, 2014, the Company has paid $131,000 in set-up fees, which were recorded as R&D expenses in the accompanying consolidated statement of operations.

Litigation and Contingencies

On June 30, 2011, Robert Kelly, the Company’s former President, filed a counterclaim against the Company in an arbitration proceeding, alleging breach of contract in connection with the termination of a consulting agreement between Mr. Kelly (dba Pitslayer LLC) and the Company that was entered into in July 2010 in connection with his resignation from the Company as President and a director. The consulting agreement was terminated by the Company in September 2010.

On February 26, 2013, Mr. Victor Cononi filed a complaint in the United States District Court, Western Division of Washington seeking compensatory damages, interest and attorneys’ fees related to the rescission of shares issued to him in July 2010 in connection with Mr. Kelly’s resignation from the Company as President and a director.

On November 3, 2014, the matters with Messrs. Kelly and Cononi were settled through mutual agreement of the parties. The parties agreed to mutual releases and to dismiss the arbitration and federal actions. The amount paid by the Company to settle this matter was not significant.

On October 10, 2013, a putative securities class action complaint, captioned Cook v. Atossa Genetics, Inc., et al., No. 2:13-cv-01836-RSM, was filed in the United States District Court for the Western District of Washington against us, certain of the Company’s directors and officers and the underwriters of the Company November 2012 initial public offering. The complaint alleges that all defendants violated Sections 11 and 12(a)(2), and that the Company and certain of its directors and officers violated Section 15, of the Securities Act by making material false and misleading statements and omissions in the offering’s registration statement, and that we and certain of our directors and officers violated Sections 10(b) and 20A of the Exchange Act and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device. This action seeks, on behalf of persons who purchased our common stock between November 8, 2012 and October 4, 2013, inclusive, damages of an unspecific amount.

On February 14, 2014, the Court appointed plaintiffs Miko Levi, Bandar Almosa and Gregory Harrison (collectively, the “Levi Group”) as lead plaintiffs, and approved their selection of co-lead counsel and liaison counsel. The Court also amended the caption of the case to read In re Atossa Genetics, Inc. Securities Litigation. No. 2:13-cv-01836-RSM. An amended complaint was filed on April 15, 2014. The Company and other defendants filed motions to dismiss the amended complaint on May 30, 2014. The plaintiffs filed briefs in opposition to these motions on July 11, 2014. The Company replied to the opposition brief on August 11, 2014. On October 6, 2014 the Court granted defendants’ motion dismissing all claims against Atossa and all other defendants. The Court’s order provided plaintiffs with a deadline of October 26, 2014 to file a motion for leave to amend their complaint and the plaintiffs did not file such a motion by that date. On October 30, 2014, the Court entered a final order of dismissal. On November 3, 2014, plaintiffs filed a notice of appeal with the Court and have appealed the Court’s dismissal order to the U.S. Court of Appeals for the Ninth Circuit. On February 11, 2015, plaintiffs filed their opening appellate brief. Defendants’ answering brief is due April 13, 2015. A hearing for the appeal has not been set.

The Company believes this lawsuit is without merit and plans to defend itself vigorously; however, failure by the Company to obtain a favorable resolution of the claims set forth in the complaint could have a material adverse effect on the Company’s business, results of operations and financial condition. Currently, the amount of such material adverse effect cannot be reasonably estimated, and no provision or liability has been recorded for these claims as of December 31, 2014. The costs associated with defending and resolving the lawsuit and ultimate outcome cannot be predicted. These matters are subject to inherent uncertainties and the actual cost, as well as the distraction from the conduct of the Company’s business, will depend upon many unknown factors and management’s view of these may change in the future.

FDA Warning Letter

On February 21, 2013, the Company received a Warning Letter (“Warning Letter”) from the FDA regarding its Mammary Aspirate Specimen Cytology Test (MASCT) System and MASCT System Collection Test (together, the “System”). The Warning Letter arises from certain FDA findings during a July 2012 inspection, to which the Company responded in August 2012, explaining why the Company believed it was in compliance with applicable regulations and/or was implementing changes responsive to the findings of the FDA inspection. The FDA alleges in the Warning Letter that following 510(k) clearance of the MASCT System, the Company changed the System in a manner that requires submission of an additional 510(k) notification to the FDA. Specifically, the FDA stated that the Instructions For Use (IFU) in the original 510(k) submission stated that the user must “Wash the collection membrane with fixative solution into the collection vial…” while the current IFU states “…apply one spray of Saccomanno’s Fixative to the collection membrane…” and that “this change fixes the NAF specimen to the filter paper rather than washing it into a collection vial.” At the time that the changes were made the Company determined and documented that the change could not significantly affect the safety or effectiveness of the MASCT System, and thus, that a new 510(k) was not required in accordance with the FDA’s guidance document entitled, “Deciding When to Submit a 510(k) for a Change to an Existing Device.” The Warning Letter also identified certain issues with respect to the Company’s marketing of the System and the Company’s compliance with FDA Good Manufacturing Practices (cGMP) regulations, among other matters. The Company responded to the Warning Letter on March 13, 2013, and identified the corrective actions that had been made, or were otherwise underway. The Company also filed a new 510(k) application for the MASCT System which was withdrawn in August 2013 after receiving feedback from the FDA.

On October 4, 2013, the Company initiated a voluntary recall of the system to address the FDA’s concerns regarding the modifications identified in the Warning Letter. As a result of this recall, this product is currently not being marketed or distributed in the United States. The Company submitted a new premarket notification, or 510(k) application, with the FDA on December 23, 2013 that covered the collection, preparation, and processing of NAF specimens and includes the spray method of fixing specimens to the collection membrane and in September 2014 the FDA rendered a decision that the ForeCYTE Breast Aspirator is not “substantially equivalent” to its predicate device. The ForeCYTE Breast Aspirator is therefore not cleared by the FDA for marketing in the United States. We cannot market or distribute the ForeCYTE Breast Aspirator within the United States until we receive clearance for this device from the FDA.

On March 14, 2014, the FDA completed a follow up inspection at the Company’s Seattle facility. A Form 483 was provided to the Company at the conclusion of the inspection. In the FDA's most recent Form 483, five inspectional observations were identified regarding the Company’s quality management system. The FDA investigator also orally identified five additional discussion points related to the Company’s product labeling prior to the recall of the MASCT System; sufficiency of the content of the Company’s pending 510(k) submission for the ForeCYTE Breast Aspirator; and other compliance issues. On March 26, 2014, the Company submitted a response to the FDA, which included its proposed corrective actions to address the FDA's observations and discussion points. On December 5, 2014, we received EIRs (Establishment Inspection Reports) from the FDA Office of Compliance which means the FDA closed our inspections. This means that the observations that resulted from the inspections have been addressed; however, the FDA will conduct additional inspections and may issue additional observations.

STOCK BASED COMPENSATION

12 Months Ended

Dec. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

NOTE 13: STOCK BASED COMPENSATION

Stock Options and Incentive Plan

On September 28, 2010, the Board of Directors approved the adoption of the 2010 Stock Option and Incentive Plan, or the 2010 Plan, to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options may be granted under the 2010 Plan until September 2020. No other awards may be granted under the 2010 Plan after the date that is 10 years from the date of stockholder approval. An aggregate of 1,000,000 shares were initially reserved for issuance in connection with awards granted under the 2010 Plan, such number of shares to be subject to adjustment as provided in the plan and in any award agreements entered into by the Company under the plan, and upon the exercise or conversion of any awards granted under the plan. On January 1, 2012, 450,275 shares were added to the 2010 Plan and on January 1, 2013, 516,774 shares were added to the 2010 Plan, and on January 1, 2014, 742,973 shares were added to the 2010 plan as provided under the terms of the 2010 Plan.

The Company granted options to purchase 2,426,669 shares of common stock to employees and directors and issued 160,000 shares of common stock in connection with the exercise of directors stock options during the year ended December 31, 2014. There are 439,388 options available for grant under the 2010 Plan as of December 31, 2014, and as a result of the evergreen provision contained in the 2010 Plan, there are 1,422,750 options available for grant under the 2010 Plan as of January 1, 2015.

Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock based compensation expense of $698,657 and $1,443,760 for the years ended December 31, 2014 and 2013, respectively.

		Year Ended December 31,
	2014		2013

General and administrative	$	556,288	$	1,168,455
Research and development		46,783		174,553
Selling		95,586		100,752
Total stock compensation expense	$	698,657	$	1,443,760

The following table presents information concerning stock option grants for the year ended December 31, 2014:

	Employees			Executives & Officers			Directors

Fair value of common stock on date of grant	$	0.96 - 2.20		$	0.96 - 2.20		$	1.22 - 2.20
Exercise price of the options	$	0.96 - 2.20		$	0.96- 2.20		$	1.22-2.20
Expected life of the options (years)		6.06- 6.11			6.06 - 6.11			5.09 – 5.31
Dividend yield		0.00	%		0.00	%		0.00	%
Expected volatility		38.83- 41.72	%		38.83 - 41.70	%		38.64 - 38.68	%

Risk-free interest rate		1.75 - 2.11	%		1.75 - 2.11	%		1.53 – 1.75	%
Expected forfeiture per year (%)		10.00	%		10.00	%		10.00	%
Weighted average fair value of the options per unit	$	0.64		$	0.56		$	0.70

Options issued and outstanding as of December 31, 2014 and their activities during the year then ended are as follows:

	Number of Underlying Shares		Weighted- Average Exercise Price Per Share		Weighted- Average Contractual Life Remaining in Years		Aggregate Intrinsic Value
Outstanding as of January 1, 2014		2,282,719	$	4.43			$	282,063
Granted		2,426,669		1.45
Forfeited		(873,754)		4.29				21,540
Exercised		(160,000)		1.25				69,388
Outstanding as of December 31, 2014		3,675,634		2.86		8.11	$	344,000
Exercisable as of December 31, 2014		1,391,749		4.34		6.31	$	37,878
Vested and expected to vest (1)		3,380,169	$	2.95		8.01	$	301,945

⁽¹⁾ vested shares and unvested shares after a forfeiture rate is applied

At December 31, 2014, there were 2,283,885 unvested options outstanding and the related unrecognized total compensation cost associated with these options was $1,506,667. This expense is expected to be recognized over a weighted-average period of 2.84 years.

Issuance of Restricted Common Stock and Stock Options for Directors’ and Executives’ Compensation

On October 10, 2013, the Company issued 24,510 shares of restricted stock with a grant date value of $50,000 or $2.04 per share to a new board member. On March 1, 2014, the Company agreed to issue 22,728 shares of restricted stock with a grant date value of $50,000 or $2.20 per share to a new board member. These share issuances were canceled in May 2014 in connection with a new compensation plan adopted by the Board of Directors for independent members of the Board and the grants were each replaced with $35,000 in cash payment.

On May 6, 2014, options to purchase a total of 15,000 shares of common stock, with exercise prices of $1.22 per share, which was the fair market value on the date of grant, were also granted under the 2010 Plan to each of our four non-employee directors for service on the Board during the year following our 2014 annual meeting of stockholders. On that date, options to purchase 665,000 shares of stock, exercisable at $1.22 per share, which was the fair market value on the date of grant, were granted to senior officers under the 2010 Plan. The options granted to non- employee directors vest quarterly over one year and options granted to the senior officers vest quarterly over four years.

In May 2014, 200,000 stock options were granted outside the 2010 Plan to the Vice President of Clinical Research and Development. The options have an exercise price of $1.25, which was the fair market value on the date of grant, and vest 25% at the end of the first year and vest quarterly thereafter over the following three years.

In June 2014, 200,000 stock options were granted outside the 2010 Plan to the Senior Vice President of Global Regulatory Affairs and Quality Assurance. The options have an exercise price of $1.41, which is the fair market value on the date of grant, and vest 25% at the end of the first year and vest quarterly thereafter over the following three years.

In September 2014, 200,000 stock options were granted outside the 2010 Plan to the Senior Vice President of Operations as an inducement grant material to hiring a new employee in this position. The options have an exercise price of $1.86, which was the fair market value on the date of grant, and vest 25% at the end of the first year and vest quarterly thereafter over the following three years.

In December 2014, 200,000 stock options were granted outside the 2010 Plan to the Vice President of European Commercial Operations as an inducement grant material to hiring a new employee in this position. The options have an exercise price of $.96 per share, which was the fair market value on the date of grant, and vest 25% at the end of the first year and vest quarterly thereafter over the following three years.

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2014

Subsequent Events [Abstract]

Subsequent Events [Text Block]

NOTE 14: SUBSEQUENT EVENTS

All subsequent events requiring recognition as of December 31, 2014 have been incorporated into these consolidated financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events”, except as follows:

Subsequent to January 1, 2015, and through March 27, 2015 the Company has sold a total of 832,066 shares of Common Stock to Aspire Capital Fund LLC under the stock purchase agreement dated November 8, 2013 with aggregate gross proceeds to the Company of $1,539,367.

SUMMARY OF ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation:

Use of Estimates, Policy [Policy Text Block]

Use of Estimates:

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Pronouncements:

Reclassification, Policy [Policy Text Block]

Reclassifications:

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Overview

Product Revenue

Service Revenue

Cost of Sales, Policy [Policy Text Block]

Cost of Revenue

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less.

Inventory, Policy [Policy Text Block]

Inventory

Trade and Other Accounts Receivable, Policy [Policy Text Block]

Accounts Receivable

Property, Plant and Equipment, Policy [Policy Text Block]

Furniture and Equipment

Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:

		Useful Life (in years)
Machinery and equipment		3 - 5
Leasehold improvements		2.083

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Intangible Assets

Amortization is computed using the straight-line method over the estimate useful lives of the assets as follows:

		Useful Life (in years)
Patents		7 - 12
Software		3

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Share-Based Payments

SUMMARY OF ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Property, Plant and Equipment Useful Life [Table Text Block]

Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:

		Useful Life (in years)
Machinery and equipment		3 - 5
Leasehold improvements		2.083

Schedule of Finite-Lived Intangible Assets [Table Text Block]

Amortization is computed using the straight-line method over the estimate useful lives of the assets as follows:

		Useful Life (in years)
Patents		7 - 12
Software		3

PREPAID EXPENSES (Tables)

12 Months Ended

Dec. 31, 2014

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]

Prepaid expenses consisted of the following:

	December 31,		December 31,
	2014		2013
Prepaid insurance	$	87,633	$	112,517
Tradeshow and other marketing events		50,000		-
Prepaid hardware and software		38,268		131,204
Retainer and security deposits		25,000		36,906
Lab supplies		14,976		-
Other		31,330		-
Total prepaid expenses	$	247,207	$	280,627

FURNITURE AND EQUIPMENT (Tables)

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Furniture and equipment consisted of the following:

	December 31,		December 31,
	2014		2013
Machinery and equipment	$	522,813	$	168,532
Leasehold improvements		93,665		93,665
Capitalized new product development cost		-		15,000
Furniture and equipment		616,478		277,197
Less: accumulated depreciation		(258,946)		(114,050)
Total furniture and equipment, net	$	357,532	$	163,147

INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets and Goodwill [Table Text Block]

Intangible assets consisted of the following:

	December 31,		December 31,
	2014		2013
Patents	$	1,630,000	$	4,794,853
Capitalized license costs		200,000		-
Software		203,038		105,839
Intangible assets		2,033,038		4,900,692
Less: accumulated amortization		(112,393)		(505,059)
Total intangible assets, net	$	1,920,645	$	4,395,633

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Future estimated amortization expenses as of December 31, 2014 for the five succeeding years and thereafter is as follows:

As of December 31,		Amounts
2015	$	213,776
2016		224,804
2017		193,443
2018		169,015
2019		169,015
Thereafter		950,592
	$	1,920,645

PAYROLL LIABILITIES (Tables)

12 Months Ended

Dec. 31, 2014

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Payroll liabilities consisted of the following:

	December 31,		December 31,
	2014		2013
Accrued bonus payable	$	752,828	$	408,362
Accrued payroll liabilities		109,653		152,400
Accrued payroll tax liabilities		194,224		19,883
Total payroll liabilities	$	1,056,705	$	580,645

STOCKHOLDERS' EQUITY (Tables)

12 Months Ended

Dec. 31, 2014

Stockholders' Equity Note [Abstract]

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

As of December 31, 2014, warrants to purchase 6,033,426 shares of common stock were outstanding including:

	Outstanding Warrants to purchase shares	Exercise price		Expiration date

2011 private placement	4,252,050	$	1.25 - 1.60	June 23, 2016
Acueity warrants	325,000		5.00	September 30, 2017
2014 public offering	1,166,849		3.00	January 29, 2019
Placement agent fees for Company’s offerings	242,027		2.12 – 12.43	March - November, 2018
Outside consulting	47,500	$	4.24	January 14, 2018

Warrants 2014 and Placement Agent Warrants [Member]

Stockholders' Equity Note [Abstract]

Schedule of Fair Value of Warrants [Table Text Block]

The following tables reflect assumptions used to determine the fair value of the 2014 Warrants:

	Fair	January 29, 2014
	Value Hierarchy Level	2014 Investor Warrants			Placement Agent Warrants

Indexed shares			1,166,849			175,027
Exercise price		$	3.00		$	3.00

Significant assumptions:
Stock price	1	$	2.50		$	2.47
Remaining term	3		5 years			5 years
Risk free rate	2		1.45	%		1.42	%
Expected volatility	3		37.96	%		37.95	%

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

NET LOSS PER SHARE (Tables)

12 Months Ended

Dec. 31, 2014

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share for the years ended December 31, 2014 and 2013:

	Year Ended December 31,
	2014	2013
Options to purchase common stock	3,675,634	2,282,719
Warrants to purchase common stock	6,033,426	4,751,550
Restricted stock units	-	-
Total	9,709,060	7,034,269

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

The benefit for income taxes differs from the benefit computed by applying the federal statutory rate to loss before income taxes as follows:

	Year Ended December 31,
	2014		2013
Expected federal income tax benefit	$	(4,983,700)	$	(3,774,648)
Share-based compensation		36,100		-
Other permanent items		9,000		4,363
Effect of change in valuation allowance		4,938,600		3,770,285
Actual federal income tax benefit	$	-	$	-

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

The components of net deferred tax assets are as follows:

	As of December 31,
	2014		2013
Deferred tax assets, current:
Allowance for doubtful accounts	$	191,900	$	120,700
Deferred rent		900		16,400
Accrued vacation		30,400		16,400
Accrued bonuses		228,100		-
Obsolete inventory		48,400		51,000
Valuation allowance, current		(499,700)		(204,500)
Net deferred tax asset, current		-		-

Deferred tax assets, long term:
Fixed assets, net		-		8,900
Intangible assets, net		841,800		29,000
Allowance for loss on fixed assets		53,800		53,800
Contribution, carryforward		300		-
Share-based compensation		732,400		546,600
Net operating loss carryforwards		9,772,300		6,144,800
Valuation allowance, long term		(11,397,400)		(6,783,100)
Deferred tax asset, long term		3,200		-

Deferred tax liabilities
Fixed assets, net		(3,200)		-
Net deferred tax asset, long term		-		-
Net deferred tax asset	$	-	$	-

COMMITMENTS AND CONTINGENCIES (Tables)

12 Months Ended

Dec. 31, 2014

Capital Leased Assets [Line Items]

Operating Leases of Lessee Disclosure [Table Text Block]

The future minimum lease payments due subsequent to December 31, 2014 under all non-cancelable operating and capital leases for the next five years are as follows:

	Operating Leases		Capital Leases
Year Ending December 31,	Amount		Amount
2015	$	499,267	$	76,025
2016		478,210		49,216
2017		119,333		-
2018		13,439		-
2019		13,439		-
Total minimum lease payments	$	1,123,688	$	125,241

Schedule of Rent Expense [Table Text Block]

The total rent expense for 2014 and 2013, respectively, is as follows:

Year Ending December 31,	2014		2013
Research and development expenses	$	227,996	$	214,301
General and administrative expenses		149,174		121,201
Total rent expense	$	377,170	$	335,502

Affymetrix Inc [Member]

Capital Leased Assets [Line Items]

Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]

The future minimum payments for the Affymetrix capital lease are as follows:

Year Ending December 31,	Amount
2015	$	70,204
2016		49,216
Total minimum lease payments	$	119,420

STOCK BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

		Year Ended December 31,
	2014		2013

General and administrative	$	556,288	$	1,168,455
Research and development		46,783		174,553
Selling		95,586		100,752
Total stock compensation expense	$	698,657	$	1,443,760

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The following table presents information concerning stock option grants for the year ended December 31, 2014:

	Employees			Executives & Officers			Directors

Fair value of common stock on date of grant	$	0.96 - 2.20		$	0.96 - 2.20		$	1.22 - 2.20
Exercise price of the options	$	0.96 - 2.20		$	0.96- 2.20		$	1.22-2.20
Expected life of the options (years)		6.06- 6.11			6.06 - 6.11			5.09 – 5.31
Dividend yield		0.00	%		0.00	%		0.00	%
Expected volatility		38.83- 41.72	%		38.83 - 41.70	%		38.64 - 38.68	%

Risk-free interest rate		1.75 - 2.11	%		1.75 - 2.11	%		1.53 – 1.75	%
Expected forfeiture per year (%)		10.00	%		10.00	%		10.00	%
Weighted average fair value of the options per unit	$	0.64		$	0.56		$	0.70

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Options issued and outstanding as of December 31, 2014 and their activities during the year then ended are as follows:

	Number of Underlying Shares		Weighted- Average Exercise Price Per Share		Weighted- Average Contractual Life Remaining in Years		Aggregate Intrinsic Value
Outstanding as of January 1, 2014		2,282,719	$	4.43			$	282,063
Granted		2,426,669		1.45
Forfeited		(873,754)		4.29				21,540
Exercised		(160,000)		1.25				69,388
Outstanding as of December 31, 2014		3,675,634		2.86		8.11	$	344,000
Exercisable as of December 31, 2014		1,391,749		4.34		6.31	$	37,878
Vested and expected to vest (1)		3,380,169	$	2.95		8.01	$	301,945

⁽¹⁾ vested shares and unvested shares after a forfeiture rate is applied

NATURE OF OPERATIONS (Details Textual)	9 Months Ended
NATURE OF OPERATIONS (Details Textual)	Sep. 30, 2012 USD ($)
Nature Of Operations [Line Items]
Cash Acquired from Acquisition	$ 400,000

GOING CONCERN (Details Textual) - USD ($)	12 Months Ended
GOING CONCERN (Details Textual) - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net Income (Loss) Attributable to Parent, Total	$ (14,657,926)	$ (10,784,708)
Cash and Cash Equivalents, at Carrying Value, Total	8,500,718	6,342,161	$ 1,725,197
Working Capital	6,900,000
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	$ (10,555,450)	$ (8,830,044)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

SUMMARY OF ACCOUNTING POLICIES (Details)	12 Months Ended
SUMMARY OF ACCOUNTING POLICIES (Details)	Dec. 31, 2014
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	2 years 30 days

SUMMARY OF ACCOUNTING POLICIES (Details 1)	12 Months Ended
SUMMARY OF ACCOUNTING POLICIES (Details 1)	Dec. 31, 2014
Patents [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life (in years)	12 years
Patents [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life (in years)	7 years
Computer Software, Intangible Asset [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life (in years)	3 years

SUMMARY OF ACCOUNTING POLICIES (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Line Items]
Loss On Reduction Of Inventory To Lower Of Cost Or Market	$ 0	$ 149,946
Inventory, Net	39,788	0
Allowance for Doubtful Accounts Receivable	564,149	354,861
Provision for Doubtful Accounts	209,288	354,861
Impairment of Long-Lived Assets Held-for-use	$ 2,352,626	$ 158,292
Estimated Annualized Forfeiture Rate	10.00%
Unclassified Indefinite-lived Intangible Assets [Member]
Accounting Policies [Line Items]
Fair Value Measurements, Valuation Techniques	Discount rates used in the Companys valuations for these intangible assets ranged from 18% to 21%.

PREPAID EXPENSES (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets [Line Items]
Prepaid insurance	$ 87,633	$ 112,517
Tradeshow and other marketing events	50,000	0
Prepaid hardware and software	38,268	131,204
Retainer and security deposits	25,000	36,906
Lab supplies	14,976	0
Other	31,330	0
Total prepaid expenses	$ 247,207	$ 280,627

FURNITURE AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Machinery and equipment	$ 522,813	$ 168,532
Leasehold improvements	93,665	93,665
Capitalized new product development cost	0	15,000
Furniture and equipment	616,478	277,197
Less: accumulated depreciation	(258,946)	(114,050)
Total furniture and equipment, net	$ 357,532	$ 163,147

FURNITURE AND EQUIPMENT (Details Textual) - USD ($)	12 Months Ended
FURNITURE AND EQUIPMENT (Details Textual) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Depreciation	$ 144,896	$ 82,970
Capital Leased Assets, Gross	$ 206,702

INTANGIBLE ASSETS (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Patents	$ 1,630,000	$ 4,794,853
Capitalized license costs	200,000	0
Software	203,038	105,839
Intangible assets	2,033,038	4,900,692
Less: accumulated amortization	(112,393)	(505,059)
Total intangible assets, net	$ 1,920,645	$ 4,395,633

INTANGIBLE ASSETS (Details 1) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
2015	$ 213,776
2016	224,804
2017	193,443
2018	169,015
2019	169,015
Thereafter	950,592
Intangible assets, net	$ 1,920,645	$ 4,395,633

INTANGIBLE ASSETS (Details Textual) - USD ($)	12 Months Ended
INTANGIBLE ASSETS (Details Textual) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net, Total	$ 1,920,645	$ 4,395,633
Finite-Lived Patents, Gross	1,630,000	4,794,853
Impairment of intangible assets	2,352,626	0
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	373,990	365,656
Computer Software, Intangible Asset [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	28,903	$ 24,308
Finite-lived Intangible Assets Acquired	$ 72,200
Finite-Lived Intangible Asset, Useful Life	3 years
Patents [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	7 years
Patents [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	12 years
Laboratory software [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired	$ 58,000
Newly developed website [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired	31,500
Software License Arrangement [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 16,667

PAYROLL LIABILITIES (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Payroll Liabilities [Line Items]
Accrued bonus payable	$ 752,828	$ 408,362
Accrued payroll liabilities	109,653	152,400
Accrued payroll tax liabilities	194,224	19,883
Total payroll liabilities	$ 1,056,705	$ 580,645

STOCKHOLDERS' EQUITY (Details)	1 Months Ended
STOCKHOLDERS' EQUITY (Details)	Jan. 29, 2014 $ / shares shares
Placement Agent Warrants [Member]
Share Based Payment Award Stock Warrants Valuation Assumptions [Line Items]
Indexed shares \| shares	175,027
Exercise price	$ 3.00
Placement Agent Warrants [Member] \| Fair Value, Inputs, Level 3 [Member]
Significant assumptions:
Remaining term	5 years
Expected volatility	37.95%
Placement Agent Warrants [Member] \| Fair Value, Inputs, Level 2 [Member]
Significant assumptions:
Risk free rate	1.42%
Placement Agent Warrants [Member] \| Fair Value, Inputs, Level 1 [Member]
Significant assumptions:
Stock price	$ 2.47
Investor Warrants 2014 [Member]
Share Based Payment Award Stock Warrants Valuation Assumptions [Line Items]
Indexed shares \| shares	1,166,849
Exercise price	$ 3.00
Investor Warrants 2014 [Member] \| Fair Value, Inputs, Level 3 [Member]
Significant assumptions:
Remaining term	5 years
Expected volatility	37.96%
Investor Warrants 2014 [Member] \| Fair Value, Inputs, Level 2 [Member]
Significant assumptions:
Risk free rate	1.45%
Investor Warrants 2014 [Member] \| Fair Value, Inputs, Level 1 [Member]
Significant assumptions:
Stock price	$ 2.50

STOCKHOLDERS' EQUITY (Details 1) - $ / shares	12 Months Ended
STOCKHOLDERS' EQUITY (Details 1) - $ / shares	Dec. 31, 2014	May 19, 2014	Jan. 29, 2014
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 15.00
2011 Private Placement [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	4,252,050
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	Jun. 23, 2016
2011 Private Placement [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.60
2011 Private Placement [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.25
Acuiety Warrants [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	325,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.00
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	Sep. 30, 2017
2014 Public Offering [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	1,166,849
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 3.00		$ 3.00
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	Jan. 29, 2019
Placement Agent Fee [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	242,027
Placement Agent Fee [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 12.43
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	Nov. 01, 2018
Placement Agent Fee [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.12
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	Mar. 01, 2018
outside consulting firm [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	47,500
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	Jan. 14, 2018

STOCKHOLDERS' EQUITY (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
STOCKHOLDERS' EQUITY (Details Textual) - USD ($)	Jan. 29, 2014	Dec. 31, 2014	May 19, 2014	Dec. 31, 2013
Stockholder's Equity [Line Items]
Total Shares Authorized		85,000,000
Common Stock, Shares Authorized		75,000,000		75,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.001		$ 0.001
Preferred Stock, Shares Authorized		10,000,000		10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.001		$ 0.001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		6,033,426
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 15.00
Percentage of Common Stock Outstanding			2.00%
Entitled to Receive Worth of Common Stock			$ 30.00
Series A Preferred Stock [Member]
Stockholder's Equity [Line Items]
Preferred Stock, Shares Authorized		750,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.001
2014 Public Offering [Member]
Stockholder's Equity [Line Items]
Shares, Issued	5,834,234
Shares Issued, Price Per Share	$ 2.40
Proceeds from Issuance or Sale of Equity	$ 14,000,000
Stockholders Equity Note, Stock Split		Each unit consists of one share of common stock and a warrant to purchase 0.20 of a share of common stock (the 2014 Investor Warrants).
Warrants Callable Per Share	$ 6.00
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 3.00	$ 3.00
Acuiety Warrants [Member]
Stockholder's Equity [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		5.00
outside consulting firm [Member]
Stockholder's Equity [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.24
Investor Warrants 2014 [Member]
Stockholder's Equity [Line Items]
Option Indexed To Issuer's Equity, Indexed Shares	1,166,849
Securities Purchase Agreements, Investor Warrants [Member]
Stockholder's Equity [Line Items]
Fair Value of Warrants (in dollars per warrant)	$ 0.72
Initial Fair Value of Warrants	$ 834,986
Placement Agent Warrants [Member]
Stockholder's Equity [Line Items]
Option Indexed To Issuer's Equity, Indexed Shares	175,027
Placement Agent [Member]
Stockholder's Equity [Line Items]
Cash Fee Equals to Percentage of Gross Proceeds from Sale of Common Stock and Warrants		7.00%
Fees and Commissions, Other	$ 980,151
Placement Agent [Member] \| Warrant [Member]
Stockholder's Equity [Line Items]
Exercise Price of Common Stock		$ 3.00
Fair Value of Warrants (in dollars per warrant)	$ 0.70
Initial Fair Value of Warrants	$ 121,707
Option Indexed To Issuer's Equity, Indexed Shares	175,027
Percentage of Shares Sold in Offering	3.00%
Minimum [Member] \| 2011 Private Placement [Member]
Stockholder's Equity [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		1.25
Maximum [Member] \| 2011 Private Placement [Member]
Stockholder's Equity [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.60
Beneficial Owner [Member]
Stockholder's Equity [Line Items]
Equity Method Investment, Ownership Percentage			15.00%

NET LOSS PER SHARE (Details) - shares	12 Months Ended
NET LOSS PER SHARE (Details) - shares	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	9,709,060	7,034,269
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,675,634	2,282,719
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,033,426	4,751,550
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	0

INCOME TAXES (Details) - USD ($)	12 Months Ended
INCOME TAXES (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Deferred
Expected federal income tax benefit	$ (4,983,700)	$ (3,774,648)
Share-based compensation	36,100	0
Other permanent items	9,000	4,363
Effect of change in valuation allowance	4,938,600	3,770,285
Actual federal income tax benefit	$ 0	$ 0

INCOME TAXES (Details 1) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets, current:
Allowance for doubtful accounts	$ 191,900	$ 120,700
Deferred rent	900	16,400
Accrued vacation	30,400	16,400
Accrued bonuses	228,100	0
Obsolete inventory	48,400	51,000
Valuation allowance, current	(499,700)	(204,500)
Net deferred tax asset, current	0	0
Deferred tax assets, long term:
Fixed assets, net	0	8,900
Intangible assets, net	841,800	29,000
Allowance for loss on fixed assets	53,800	53,800
Contribution, carryforward	300	0
Share-based compensation	732,400	546,600
Net operating loss carryforwards	9,772,300	6,144,800
Valuation allowance, long term	(11,397,400)	(6,783,100)
Deferred tax asset, long term	3,200	0
Deferred Tax Liabilities
Fixed assets, net	(3,200)	0
Net deferred tax asset, long term	0	0
Net deferred tax asset	$ 0	$ 0

INCOME TAXES (Details Textual) - USD ($)	12 Months Ended
INCOME TAXES (Details Textual) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Line Items]
Operating Loss Carryforwards, Description	2029 through 2034
Income Tax Examination, Description	The Company files income tax returns in the U.S. The Company is subject to tax examinations for the 2011 tax year and beyond.
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	$ 28,700,000
Deferred Tax Assets, Valuation Allowance	$ 11,897,100	$ 6,987,600

CONCENTRATION OF CREDIT RISK (Details Textual) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Concentration Risk [Line Items]
Cash, FDIC Insured Amount	$ 250,000
Cash, Uninsured Amount	$ 8,250,718	$ 6,092,161

COMMITMENTS AND CONTINGENCIES (Details)	Dec. 31, 2014 USD ($)
Operating Leased Assets [Abstract]
2015	$ 499,267
2016	478,210
2017	119,333
2018	13,439
2019	13,439
Total minimum lease payments	1,123,688
Capital Leased Assets [Abstract]
2015	76,025
2016	49,216
2017	0
2018	0
2019	0
Total minimum lease payments	$ 125,241

COMMITMENTS AND CONTINGENCIES (Details 1) - USD ($)	12 Months Ended
COMMITMENTS AND CONTINGENCIES (Details 1) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expenses	$ 227,996	$ 214,301
General and administrative expenses	149,174	121,201
Total rent expense	$ 377,170	$ 335,502

COMMITMENTS AND CONTINGENCIES (Details 2)	Dec. 31, 2014 USD ($)
Capital Leased Assets [Line Items]
2015	$ 76,025
2016	49,216
Total minimum lease payments	125,241
Affymetrix Inc [Member]
Capital Leased Assets [Line Items]
2015	70,204
2016	49,216
Total minimum lease payments	$ 119,420

COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($)		1 Months Ended	3 Months Ended	12 Months Ended
	Sep. 02, 2014	Sep. 30, 2014	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
COMMITMENTS AND CONTINGENCIES [Line Items]
Cost of Services				$ 340,658	$ 105,764
Research and Development Expense, Total				2,577,465	1,105,110
Capital Leased Assets, Gross				$ 206,702
Amortization Of Capital Lease Equipment Straight Line Basis				5 years
Other Commitments, Description		On September 1, 2014, the NRLBH entered into a three year agreement with TME Research LLC (TME) which requires TME to provide to the NRLBH 100 tissue specimens in connection with the development of the NextCYTE test. Fees payable to TME under the agreement includes $99,600 up front, $31,500 upon supplying the first 25 specimens and $31,500 at the time of final delivery of all specimens. The agreement is terminable with 60 days prior written notice or immediately upon a material breach.
Upfront Fee Payable Under Targeted Medical Education Agreement		$ 99,600
Fee Payable Upon Supply Of First Specimen Under Targeted Medical Education Agreement		31,500
Fee Payable Upon Final Delivery Under Targeted Medical Education Agreement		31,500
Targeted Medical Education [Member] \| Master Service Agreement [Member]
COMMITMENTS AND CONTINGENCIES [Line Items]
Research and Development Expense, Total				$ 131,000
A5 Genetics KFT [Member]
COMMITMENTS AND CONTINGENCIES [Line Items]
Cost of Services, Licenses and Services					100,000
Additional License Fee Amount Paid			$ 100,000
Additional License Fee Obligation Amount			1,200,000
Royalty Expense			50
Cost of Services			$ 65
Affymetrix In [Member] \| OwnerChip Program Agreement [Member] \| Subsidiaries [Member]
COMMITMENTS AND CONTINGENCIES [Line Items]
Payments for Software				21,590	$ 94,723
Purchase Obligation		$ 142,005		647,700
Contract Payable, Due in Rolling Year Two				$ 51,600
NRLBH [Member]
COMMITMENTS AND CONTINGENCIES [Line Items]
Minimum Purchase Under License Agreement to Acquire Right	$ 452,408

STOCK BASED COMPENSATION (Details) - USD ($)	12 Months Ended
STOCK BASED COMPENSATION (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount	$ 698,657	$ 1,443,760
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount	556,288	1,168,455
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount	46,783	174,553
Selling [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount	$ 95,586	$ 100,752

STOCK BASED COMPENSATION (Details 1)	12 Months Ended
STOCK BASED COMPENSATION (Details 1)	Dec. 31, 2014 $ / shares
Employees [Member]
Share Based Payment Award Stock Options Valuation Assumption [Line Items]
Dividend yield	0.00%
Expected forfeiture per year (%)	10.00%
Weighted average fair value of the options per unit	$ 0.64
Employees [Member] \| Minimum [Member]
Share Based Payment Award Stock Options Valuation Assumption [Line Items]
Fair value of common stock on date of grant	0.96
Exercise price of the options	$ 0.96
Expected life of the options (years)	6 years 22 days
Expected volatility	38.83%
Risk-free interest rate	1.75%
Employees [Member] \| Maximum [Member]
Share Based Payment Award Stock Options Valuation Assumption [Line Items]
Fair value of common stock on date of grant	$ 2.20
Exercise price of the options	$ 2.20
Expected life of the options (years)	6 years 1 month 10 days
Expected volatility	41.72%
Risk-free interest rate	2.11%
Directors [Member]
Share Based Payment Award Stock Options Valuation Assumption [Line Items]
Dividend yield	0.00%
Expected forfeiture per year (%)	10.00%
Weighted average fair value of the options per unit	$ 0.70
Directors [Member] \| Minimum [Member]
Share Based Payment Award Stock Options Valuation Assumption [Line Items]
Fair value of common stock on date of grant	1.22
Exercise price of the options	$ 1.22
Expected life of the options (years)	5 years 1 month 2 days
Expected volatility	38.64%
Risk-free interest rate	1.53%
Directors [Member] \| Maximum [Member]
Share Based Payment Award Stock Options Valuation Assumption [Line Items]
Fair value of common stock on date of grant	$ 2.20
Exercise price of the options	$ 2.20
Expected life of the options (years)	5 years 3 months 22 days
Expected volatility	38.68%
Risk-free interest rate	1.75%
Executives and Officers [Member]
Share Based Payment Award Stock Options Valuation Assumption [Line Items]
Dividend yield	0.00%
Expected forfeiture per year (%)	10.00%
Weighted average fair value of the options per unit	$ 0.56
Executives and Officers [Member] \| Minimum [Member]
Share Based Payment Award Stock Options Valuation Assumption [Line Items]
Fair value of common stock on date of grant	0.96
Exercise price of the options	$ 0.96
Expected life of the options (years)	6 years 22 days
Expected volatility	38.83%
Risk-free interest rate	1.75%
Executives and Officers [Member] \| Maximum [Member]
Share Based Payment Award Stock Options Valuation Assumption [Line Items]
Fair value of common stock on date of grant	$ 2.20
Exercise price of the options	$ 2.20
Expected life of the options (years)	6 years 1 month 10 days
Expected volatility	41.70%
Risk-free interest rate	2.11%

STOCK BASED COMPENSATION (Details 2)

12 Months Ended

Dec. 31, 2014

USD ($)

$ / shares

Share Based Compensation Stock Options Activity [Line Items]

Number of Underlying Shares, Outstanding as of January 1, 2014 (in shares) | shares

2,282,719

Number of Underlying Shares, Granted (in shares) | shares

2,426,669

Number of Underlying Shares, Forfeited (in shares) | shares

(873,754)

Number of Underlying Shares, Exercised (in shares) | shares

(160,000)

Number of Underlying Shares, Outstanding as of December 31, 2014 (in shares) | shares

3,675,634

Number of Underlying Shares, Exercisable as of December 31, 2014 (in shares) | shares

1,391,749

Number of Underlying Shares, Vested and expected to vest (in shares) | shares

3,380,169

^[1]

Weighted-Average Exercise Price Per Share, Outstanding as of January 1, 2014 (in dollars per share) | $ / shares

$ 4.43

Weighted-Average Exercise Price Per Share, Granted (in dollars per share) | $ / shares

1.45

Weighted-Average Exercise Price Per Share, Forfeited (in dollars per share) | $ / shares

4.29

Weighted-Average Exercise Price Per Share, Exercised (in dollars per share) | $ / shares

1.25

Weighted-Average Exercise Price Per Share, Outstanding as of December 31, 2014 (in dollars per share) | $ / shares

2.86

Weighted-Average Exercise Price Per Share, Exercisable as of December 31, 2014 (in dollars per share) | $ / shares

4.34

Weighted-Average Exercise Price Per Share, Vested and expected to vest (in dollars per share) | $ / shares

$ 2.95

^[1]

Weighted-Average Contractual Life Remaining in Years, Outstanding as of December 31, 2014

8 years 1 month 10 days

Weighted-Average Contractual Life Remaining in Years, Exercisable as of December 31, 2014

6 years 3 months 22 days

Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest

8 years 4 days

^[1]

Aggregate Intrinsic Value, Outstanding as of January 1, 2014 | $

$ 282,063

Aggregate Intrinsic Value, Forfeited (in dollars) | $

21,540

Aggregate Intrinsic Value, Exercised (in dollars) | $

69,388

Aggregate Intrinsic Value, Outstanding as of December 31, 2014 | $

344,000

Aggregate Intrinsic Value, Exercisable as of December 31, 2014 | $

37,878

Aggregate Intrinsic Value, Vested and expected to vest | $

$ 301,945

^[1]

[1]	vested shares and unvested shares after a forfeiture rate is applied

STOCK BASED COMPENSATION (Details Textual) - USD ($)			1 Months Ended			12 Months Ended
STOCK BASED COMPENSATION (Details Textual) - USD ($)	May 06, 2014	Oct. 10, 2013	Sep. 30, 2014	Jun. 30, 2014	May 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 28, 2010
Stock-based Compensation [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price						$ 1.45
Stock Issued During Period, Shares, Restricted Stock Award, Gross		24,510			22,728
Stock Issued During Period, Value, Restricted Stock Award, Gross		$ 50,000			$ 50,000
Share-based Compensation						$ 698,657	$ 1,443,760
Directors Compensation Paid					$ 35,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross						2,426,669
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						2 years 10 months 2 days
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant						1,422,750
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares						2,283,885
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized						$ 1,506,667
Stock Option Two [Member]
Stock-based Compensation [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant						0
Stock Option and Incentive Plan 2010 [Member]
Stock-based Compensation [Line Items]
Shares held in Employee Stock Option Plan, Suspense Shares						742,973	516,774	450,275	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant						439,388
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures						160,000
Stock Options Were Granted Outside Of 2010 Plan [Member]
Stock-based Compensation [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross			200,000	200,000	200,000	200,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighted Average Grant Date Fair Value			$ 1.86	$ 1.41	$ 1.25	$ 0.96
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights			vest 25% at the end of the first year and vest quarterly thereafter over the following three years.	vest 25% at the end of the first year and vest quarterly thereafter over the following three years.	vest 25% at the end of the first year and vest quarterly thereafter over the following three years.	vest 25% at the end of the first year and vest quarterly thereafter over the following three years.
Restricted Stock [Member]
Stock-based Compensation [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 2.04			$ 2.20
Non-Employee Director [Member]
Stock-based Compensation [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year
Non-Employee Director [Member] \| Minimum [Member]
Stock-based Compensation [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighted Average Grant Date Fair Value						$ 1.22
Non-Employee Director [Member] \| Maximum [Member]
Stock-based Compensation [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighted Average Grant Date Fair Value						$ 2.20
Non-Employee Director [Member] \| Stock Option One [Member]
Stock-based Compensation [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	15,000
Non-Employee Director [Member] \| Stock Option and Incentive Plan 2010 [Member] \| Stock Option One [Member]
Stock-based Compensation [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighted Average Grant Date Fair Value	$ 1.22
Senior Officers [Member]
Stock-based Compensation [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	665,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Senior Officers [Member] \| Stock Option and Incentive Plan 2010 [Member]
Stock-based Compensation [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighted Average Grant Date Fair Value	$ 1.22
Employees And Directors [Member]
Stock-based Compensation [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross						2,426,669

SUBSEQUENT EVENTS (Details Textual) - Aspire Capital Fund, Llc [Member] - Subsequent Event [Member]	3 Months Ended
	Mar. 27, 2015 USD ($) shares
Stock Issued During Period, Shares, New Issues \| shares	832,066
Proceeds from Issuance of Common Stock \| $	$ 1,539,367